Edwards Lifesciences wins FDA approval for SAPIEN M3, the first transseptal TMVR, expanding minimally invasive options for high-risk mitral regurgitation patients.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the company's SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach to receive U.S. Food and Drug Administration (FDA) approval for the treatment of mitral regurgitation (MR). The SAPIEN M3 transcatheter mitral valve replacement (TMVR) system is indicated for the treatment of symptomatic moderate-to-severe or severe MR in patients who are deemed unsuitable for.

Four large-cap MedTech leaders, MDT, ISRG, CAH, EW, appear well-positioned to extend their winning streaks in 2026 on resilient procedure demand and innovation.

Thrivent Financial for Lutherans lifted its holdings in Edwards Lifesciences Corporation (NYSE: EW) by 24.6% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 50,857 shares of the medical research company's stock after buying an additional 10,045 shares during the

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Monday, Jan. 12, 2026. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived ve.

Edwards Lifesciences leans on growth in Surgical Structural Heart, TAVR and TMTT, though macro pressures and litigation continue to weigh on margins.

Edwards Lifesciences Corporation (EW) Analyst/Investor Day Transcript

Arrowstreet Capital Limited Partnership reduced its position in Edwards Lifesciences Corporation (NYSE: EW) by 42.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 153,874 shares of the medical research company's stock after selling 112,182 shares during

Edgestream Partners L.P. lowered its stake in Edwards Lifesciences Corporation (NYSE: EW) by 97.0% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,695 shares of the medical research company's stock after selling 117,875 shares during the period. Edgestream Partners L.P.'s holdings in